Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Komal L Jhaveri

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 20, 2025
After a CDK4/6 Inhibitor: State of the Art in Hormone Receptor-Positive Metastatic Breast CancerJimmitti Teysir, Maxwell R Lloyd, Samer Alkassis, et al.
Breast Cancer Research and Treatment|June 10, 2021
A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imagingAki Morikawa, Milan Grkovski, Sujata Patil, et al.
NPJ Breast Cancer|December 4, 2025
Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinionNeil M Iyengar, Joyce A O'Shaughnessy, Heather B Moore, et al.
The New England Journal of Medicine|June 2, 2025
Overall Survival with Inavolisib in <i>PIK3CA</i>-Mutated Advanced Breast CancerKomal L Jhaveri, Seock-Ah Im, Cristina Saura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2022
Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast CancerHope S Rugo, Aditya Bardia, Frederik Marmé, et al.
JCO Precision Oncology|December 7, 2020
Measuring Tumor Epichaperome Expression Using [<sup>124</sup>I] PU-H71 Positron Emission Tomography as a Biomarker of Response for PU-H71 Plus Nab-Paclitaxel in HER2-Negative Metastatic Breast CancerKomal L Jhaveri, Carlos H Dos Anjos, Tony Taldone, et al.
Breast Cancer Research and Treatment|July 3, 2020
Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancerDiana G Wang, Dulce M Barrios, Victoria S Blinder, et al.
Lancet (London, England)|August 26, 2023
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trialHope S Rugo, Aditya Bardia, Frederik Marmé, et al.
Cancer Research Communications|August 5, 2025
Phase 2 Study of Zilovertamab Vedotin in Participants With Metastatic Solid TumorsFunda Meric-Bernstam, Martin Gutierrez, Enrique Sanz-Garcia, et al.
NPJ Breast Cancer|April 27, 2026
Imlunestrant with or without abemaciclib in advanced breast cancer: safety analyses from the EMBER-3 trialJoyce O'Shaughnessy, Francois-Clement Bidard, Patrick Neven, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 20, 2025
After a CDK4/6 Inhibitor: State of the Art in Hormone Receptor-Positive Metastatic Breast CancerJimmitti Teysir, Maxwell R Lloyd, Samer Alkassis, et al.
Breast Cancer Research and Treatment|June 10, 2021
A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imagingAki Morikawa, Milan Grkovski, Sujata Patil, et al.
NPJ Breast Cancer|December 4, 2025
Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinionNeil M Iyengar, Joyce A O'Shaughnessy, Heather B Moore, et al.
The New England Journal of Medicine|June 2, 2025
Overall Survival with Inavolisib in <i>PIK3CA</i>-Mutated Advanced Breast CancerKomal L Jhaveri, Seock-Ah Im, Cristina Saura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2022
Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast CancerHope S Rugo, Aditya Bardia, Frederik Marmé, et al.
JCO Precision Oncology|December 7, 2020
Measuring Tumor Epichaperome Expression Using [<sup>124</sup>I] PU-H71 Positron Emission Tomography as a Biomarker of Response for PU-H71 Plus Nab-Paclitaxel in HER2-Negative Metastatic Breast CancerKomal L Jhaveri, Carlos H Dos Anjos, Tony Taldone, et al.
Breast Cancer Research and Treatment|July 3, 2020
Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancerDiana G Wang, Dulce M Barrios, Victoria S Blinder, et al.
Lancet (London, England)|August 26, 2023
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trialHope S Rugo, Aditya Bardia, Frederik Marmé, et al.
Cancer Research Communications|August 5, 2025
Phase 2 Study of Zilovertamab Vedotin in Participants With Metastatic Solid TumorsFunda Meric-Bernstam, Martin Gutierrez, Enrique Sanz-Garcia, et al.
NPJ Breast Cancer|April 27, 2026
Imlunestrant with or without abemaciclib in advanced breast cancer: safety analyses from the EMBER-3 trialJoyce O'Shaughnessy, Francois-Clement Bidard, Patrick Neven, et al.
Pageof 2